PATENT CLAIM ANALYSIS

Application Number: 16052724
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-06
Patent Classification: ["514", "549000"]

Abstract:
In various embodiments, the present invention provides methods of treating and/or preventing pediatric metabolic syndrome comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Claim (Index 22):
The method of  claim 1  wherein upon treatment the subject exhibits one or more of the following outcomes: (a) reduced triglyceride levels compared to baseline; (b) reduced Apo B levels compared to baseline; (c) increased HDL-C levels compared to baseline; (d) no increase in LDL-C levels compared to baseline; (e) a reduction in LDL-C levels compared to baseline; ( 0  a reduction in non-HDL-C levels compared to baseline; (g) a reduction in VLDL levels compared to baseline; (h) an increase in apo A-I levels compared to baseline; (i) an increase in apo A-I/apo B ratio compared to baseline; (j) a reduction in lipoprotein a levels compared to baseline; (k) a reduction in LDL particle number compared to baseline; (l) an increase in LDL size compared to baseline; (m) a reduction in remnant-like particle cholesterol compared to baseline; (n) a reduction in oxidized LDL compared to baseline; (o) a less than 5% change in fasting plasma glucose (FPG) compared to baseline; (p) a less than 5% change in hemoglobin A 1c  (HbA 1c ) compared to baseline; (q) a reduction in homeostasis model insulin resistance compared to baseline; (r) a reduction in lipoprotein associated phospholipase A2 compared to baseline; (s) a reduction in intracellular adhesion molecule compared to baseline; (t) a reduction in interleukin-6 compared to baseline; (u) a reduction in plasminogen activator inhibitor compared to baseline; (v) a reduction in high sensitivity C-reactive protein (hsCRP) compared to baseline; (w) an increase in serum phospholipid EPA compared to baseline; and/or (x) an increase in red blood cell membrane EPA compared to baseline.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 96.0
- Lexical Diversity: 1.12903
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13282145', '13711329', '13349157', '13349153', '13711324']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7188605426967551
- 35 USC 102 Novelty (BERT): 0.5252682085453267
- Combined Prediction Score: 0.6995013092816122
- Mean Citation Score: 291.38515399999994
- Max Citation Score: 292.50858
- Similarity Product: 187.1768240893436

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test